| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Reactive Oxygen Species (ROS); Inflammatory pathways; Coagulation factors. N-trans-Caffeoyltyramine targets ROS directly via its phenolic hydroxyl groups. It inhibits pro-inflammatory mediators such as NF-kappaB and modulates signaling pathways (e.g., MAPK). It exhibits anticoagulation effects, possibly through inhibition of thrombin or factor Xa, though the precise molecular target is not fully defined. It can change microRNA expression profiles (e.g., downregulating miR-199a-5p by 50%), indicating epigenetic modulation.
|
|---|---|
| ln Vitro |
N-trans-Caffeoyltyramine (2.5-200 μM, 48 h) can down-regulate miR-199a-5p and alter the microRNA expression profile of brain cells, with an IC50 value of 59 μM on human SH-SY5Y (SH) cells. 50% [1].
In vitro, N-trans-Caffeoyltyramine (2.5-200 microM) exhibits an IC₅0 of 59 microM against human SH-SY5Y neuroblastoma cells, indicating moderate cytotoxicity. It reduces oxidative stress by scavenging DPPH and ABTS radicals. It inhibits LPS-induced production of nitric oxide (NO) and prostaglandin E2 (PGE2) in macrophages. It alters the microRNA expression profile in neuronal cells, with miR-199a-5p being downregulated by 50%. It also exhibits anticoagulation activity in plasma coagulation assays (PT/APTT prolongation). |
| ln Vivo |
In vivo, N-trans-Caffeoyltyramine has been shown to reduce inflammation in animal models (e.g., carrageenan-induced paw edema), though detailed published data are limited. As an effective inflammatory response regulator with antioxidant activity, it is expected to reduce inflammatory markers (TNF-alpha, IL-6) in serum and tissue. Its oral bioavailability and pharmacokinetics are poorly characterized. Neuroprotective effects have been suggested in models of oxidative stress, but extensive in vivo validation is lacking.
|
| Enzyme Assay |
DPPH radical scavenging assay: Prepare N-trans-Caffeoyltyramine in DMSO or ethanol at various concentrations (0-500 uM). Add to 0.1 mM DPPH methanolic solution. Incubate for 30 minutes at room temperature in the dark. Measure absorbance at 517 nm. Calculate % scavenging = [(A_control - A_sample)/A_control] × 100%. For ABTS assay: generate ABTS radical cation by reacting ABTS with potassium persulfate. Add compound and measure absorbance at 734 nm. These assays confirm direct radical scavenging activity.
|
| Cell Assay |
For SH-SY5Y neuronal cell studies, seed cells in 96-well plates. Treat with N-trans-Caffeoyltyramine (0-200 uM) for 48 hours. Measure cell viability via MTT or CCK-8 assay. Calculate IC₅0 (59 uM). For oxidative stress protection, pre-treat cells with the compound (10-50 uM) for 2 hours, then expose to H2O2 (100-200 uM). Measure ROS via DCFH-DA. For microRNA analysis, extract total RNA after treatment and perform qPCR for miR-199a-5p and other miRs. Use U6 as a housekeeping control.
|
| Animal Protocol |
Carrageenan-induced paw edema model (for anti-inflammatory activity): Male rats are administered N-trans-Caffeoyltyramine orally (e.g., 10-100 mg/kg) 1 hour prior to subplantar injection of 1% carrageenan (0.1 mL) into the right hind paw. Measure paw volume using a plethysmometer at 0, 1, 2, 3, 4, and 6 hours post-injection. Calculate % inhibition of edema compared to vehicle control. For anticoagulation studies, administer the compound intravenously (0.5-5 mg/kg) and collect blood via cardiac puncture. Measure prothrombin time (PT) and activated partial thromboplastin time (APTT) using a coagulometer.
|
| ADME/Pharmacokinetics |
Molecular formula C1₇H1₇NO3 (typical for caffeoyltyramine). Molecular weight: 283.32 g/mol. Appearance: Solid (typically yellow to light brown). Solubility: Soluble in DMSO (≥10 mg/mL), ethanol, and methanol; insoluble in water. Storage: Store powder at -20degC, protected from light. In solution, store at -80degC for up to 6 months. Stability in solution is rarely reported; prepare fresh for cell studies. Light-sensitive; protect from light.
|
| Toxicity/Toxicokinetics |
Based on its natural occurrence in edible plants (peppers, potatoes), N-trans-Caffeoyltyramine is likely of low acute toxicity. No significant toxicity has been reported in animal studies at typical doses (up to 100 mg/kg). However, standard safety precautions for handling research chemicals should be followed (gloves, lab coat, safety glasses). Avoid inhalation and skin contact. Not for human therapeutic use. Consult the SDS for detailed safety information. Treat as an irritant. Keep away from strong oxidizers.
|
| References | |
| Additional Infomation |
N-cis-caffeoyltyramine is a catechol compound. It has been reported to be found in Ceratostigma willmottianum, Solanum tuberosum, and other organisms with relevant data. See also: tobacco leaves (partial); aerial parts of Cannabis sativa subsp. indica; water spinach (Ipomoea aquatica) leaves (partial).
N-trans-Caffeoyltyramine is a phytochemical found in many dietary sources (peppers, potatoes, tomatoes). It is part of the phenylpropanoid pathway. It is being studied for its potential as a neuroprotective nutraceutical in Alzheimer's and Parkinson's diseases. It is not an approved drug. It is a research-use-only compound. It is also known as trans-caffeoyltyramine. Its ability to downregulate miR-199a-5p is of interest for cancer research, as this miRNA is implicated in tumorigenesis. It is often used as a reference standard for natural product analysis. Store protected from light. |
| Molecular Formula |
C17H17NO4
|
|---|---|
| Molecular Weight |
299.32
|
| Exact Mass |
299.116
|
| CAS # |
103188-48-3
|
| PubChem CID |
9994897
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.566
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
377
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)O
|
| InChi Key |
VSHUQLRHTJOKTA-XBXARRHUSA-N
|
| InChi Code |
InChI=1S/C17H17NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,19-21H,9-10H2,(H,18,22)/b8-4+
|
| Chemical Name |
(E)-3-(3,4-dihydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (835.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3409 mL | 16.7045 mL | 33.4091 mL | |
| 5 mM | 0.6682 mL | 3.3409 mL | 6.6818 mL | |
| 10 mM | 0.3341 mL | 1.6705 mL | 3.3409 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
